- New data to be presented from in vivo study of GNS561 alone or in combination with a PD-1 inhibitor in a transgenic mouse model of hepatocarcinoma (HCC)
- In addition to good tolerance, GNS561 in combination with a PD-1 inhibitor showed significant antitumoral activity, with a 77% decrease in the macronodule counts compared to control group
- New data shows GNS561 allows PD-1 inhibitor to recover its antitumoral efficacy
Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and developing anticancer treatment drugs, today announces that its poster demonstrating promising results from a combination study with a PD-1 inhibitor in a transgenic mouse model of hepatocarcinoma (HCC) was selected for presentation at the American Association for the Study of Liver Diseases (AALSD) Liver Meeting 2019 being held November 8-12, 2019 in Boston, MA.
The in vivo study was performed in a transgenic immunocompetent mouse model of HCC (ASV-B). Animals were treated by vehicle, GNS561 or PD-1 inhibitor as monotherapy or GNS561 in combination with PD-1 inhibitor. Results showed an outstanding anticancer response, with a 77% decrease of the macronodule count in the combination group compared to controls.
“We are delighted to be presenting this positive in vivo study at the AASLD Liver Meeting 2019. These results may open a new horizon in the area of immuno-oncology by enlarging indication of the use of immune checkpoint inhibitors in tumor types that are marginally sensitive to immunotherapy or for patients developing resistance to checkpoint inhibitors. We believe our results provide a strong rationale for combining our drug to a PD-1 inhibitor antibody in clinical trials with HCC patients” said Pr Eric Raymond, Chief Medical Officer at Genoscience Pharma. “We are looking forward to assessing this combination in HCC patients, for which immunotherapy hasn’t answered the current medical need” commented Pr Philippe Halfon, President and founder of Genoscience Pharma.
Genoscience Pharma will be also presenting three additional posters at this conference. Data on the primary results of the ongoing Phase 1b assessing GNS561 in patients with primary or secondary liver cancers will be presented as well as efficacy preclinical data against intra-hepatic cholangiocarcinoma and liver fibrosis.
The details for the Company’s poster presentation are as follows:
Presenting Author: Philippe Halfon, MD, PhD.
Abstract title: GNS561, a New Oral Clinical-Stage Small Molecule Combined with a PD-1 Inhibitor Showed Remarkable Anti-Tumor Effects in a Transgenic Immunocompetent Hepatocellular Carcinoma Mouse Model (ASV-B). Poster 1993.
Presentation date and time: November 11, 2019 (presentation from 12.30 pm to 1.30 pm)
For additional information about this poster, please visit our website and contact us.
About the AASLD 2019 Liver Meeting
AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists (including Hans Popper, Leon Schiff, Fred Hoffbauer, Cecil Watson, Jesse Bollman, and Sheila Sherlock, to name a few) to bring together those who had contributed to the field of hepatology.
The annual AASLD Liver Meeting has grown to an international society responsible for all aspects of hepatology, and our annual meeting, AASLD, has grown in attendance from 12 to more than 12,500 physicians, surgeons, researchers, and allied health professionals from around the world. For more information, please visit the conference website.
About Genoscience Pharma
Genoscience Pharma, a French clinical-stage biotechnology company, is developing a potential new disruptive standard of care against liver cancers thanks to our platform. The hit lead GNS561 is an investigational best-in-class drug, tackling cancer cells through lysosomal membrane permeabilization, and shows outstanding results during its preclinical development and preliminary first-in-human clinical data. In addition to killing cancer cells, for the first time, our small molecule is capable to kill cancer stem cells, bringing a new hope to overcome cancer resistance. Following an exploration of liver cancer business potential, the company decided to focus on malignant diseases encountering highly unmet medical needs: primary and secondary liver cancers. We are collaborating with several clinical investigators in Europe and in the US that expressed their interest in GNS561.
This press release may involve and contain forward-looking statements by the company about its product candidate GNS561, including its potential benefits. Such statements are based upon the current beliefs and expectations of Genoscience Pharma’s management and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, but are not limited to: additional financing, the company’s ability to implement its chosen strategy, dependence upon third parties, other risks and uncertainties inherent in research and development, including the possibility of unfavorable study results, changes in the competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company’s growth. There are no guarantees that future clinical trials will be completed or successful or that any Genoscience Pharma therapeutics will receive regulatory approval for any indication or prove to be commercially successful. While those factors presented here are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof; Genoscience Pharma does not undertake any obligation to update such statements to reflect subsequent events or circumstances.